LUBIPROSTONE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for lubiprostone and what is the scope of freedom to operate?
Lubiprostone
is the generic ingredient in two branded drugs marketed by Sucampo Pharma Llc, Amneal, Dr Reddys, Endo Operations, Teva Pharms Usa Inc, and Zydus Pharms, and is included in six NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Lubiprostone has seventy-two patent family members in nineteen countries.
There are ten drug master file entries for lubiprostone. Sixteen suppliers are listed for this compound.
Summary for LUBIPROSTONE
International Patents: | 72 |
US Patents: | 5 |
Tradenames: | 2 |
Applicants: | 6 |
NDAs: | 6 |
Drug Master File Entries: | 10 |
Finished Product Suppliers / Packagers: | 16 |
Raw Ingredient (Bulk) Api Vendors: | 87 |
Clinical Trials: | 47 |
Patent Applications: | 1,898 |
Drug Prices: | Drug price trends for LUBIPROSTONE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LUBIPROSTONE |
What excipients (inactive ingredients) are in LUBIPROSTONE? | LUBIPROSTONE excipients list |
DailyMed Link: | LUBIPROSTONE at DailyMed |
Recent Clinical Trials for LUBIPROSTONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Alexandria University | Phase 3 |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 4 |
Helwan University | Phase 3 |
Pharmacology for LUBIPROSTONE
Drug Class | Chloride Channel Activator |
Mechanism of Action | Chloride Channel Activators |
Medical Subject Heading (MeSH) Categories for LUBIPROSTONE
Anatomical Therapeutic Chemical (ATC) Classes for LUBIPROSTONE
Paragraph IV (Patent) Challenges for LUBIPROSTONE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
AMITIZA | Capsules | lubiprostone | 8 mcg and 24 mcg | 021908 | 1 | 2012-08-20 |
US Patents and Regulatory Information for LUBIPROSTONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amneal | LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 209450-002 | Nov 30, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Dr Reddys | LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 206994-001 | Feb 8, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Amneal | LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 209450-001 | Nov 30, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LUBIPROSTONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LUBIPROSTONE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 553434 | Prostaglandin derivatives for treating gastrointestinal disorder | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2007086536 | ⤷ Sign Up | |
Portugal | 1978944 | ⤷ Sign Up | |
South Korea | 20170003712 | 위장 장애 치료를 위한 프로스타글란딘 유도체 (PROSTAGLANDIN DERIVATIVES FOR TREATING GASTROINTESTINAL DISORDER) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LUBIPROSTONE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2298314 | 92826 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: LUBIPROSTONE, INCLUANT LES SELS PHARMACEUTIQUEMENT ACCEPTABLES, LES ESTERS OU LES AMIDES DE LA LUBIPROSTONE. FIRST REGISTRATION: 20120910 |
1315485 | 132016000025193 | Italy | ⤷ Sign Up | PRODUCT NAME: LUBIPROSTONE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(AMITIZA); AUTHORISATION NUMBER(S) AND DATE(S): PL 21341/0003, 20120910;043833019-021, 20150526 |
1315485 | 2015C/048 | Belgium | ⤷ Sign Up | PRODUCT NAME: LUBIPROSTONE; AUTHORISATION NUMBER AND DATE: PL21341/0003 20150317 |
1315485 | 2015/028 | Ireland | ⤷ Sign Up | PRODUCT NAME: LUBIPROSTONE AND PHARMACEUTICALLY ACCEPTABLE SALTS FOR LUBIPROSTONE.; NAT REGISTRATION NO/DATE: PA148/002/001 20150213; FIRST REGISTRATION NO/DATE: PL21341/0003-0001 20120910 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.